Endothelial markers and homocysteine in patients with classic Fabry disease

• Published in: Acta Paediatrica Vol. 91; no. s439; pp. 57 - 61
• Main Authors: Demuth, K, Germain, DP
• Format: Journal Article
• Language: English
• Published: Oxford, UK Blackwell Publishing Ltd 01.11.2002
• Subjects: Adolescent; Adult; carbamazepine; Cohort Studies; Creatinine - blood; E-Selectin - blood; Endothelin-1 - blood; Fabry disease; Fabry Disease - blood; Fabry Disease - complications; Fabry Disease - therapy; homocysteine; Homocysteine - blood; Humans; Intercellular Adhesion Molecule-1 - blood; Male; Middle Aged; P-Selectin - blood; surrogate marker; Thrombomodulin - blood; vascular cell adhesion molecule-1; Vascular Cell Adhesion Molecule-1 - blood; Vascular Diseases - blood; Vascular Diseases - etiology; Vascular Diseases - therapy
• ISSN: 0803-5253; 0803-5326; 1651-2227
• DOI: 10.1111/j.1651-2227.2002.tb03112.x

Aim: Fabry disease is an X‐linked inborn error of glycosphingolipid metabolism due to the deficient activity of α‐galactosidase A, a lysosomal enzyme. It is a multisystem disorder characterized by progressive renal insufficiency, with added morbidity from cardio‐ and cerebrovascular involvement. The recent availability of genetically engineered enzyme offers an effective targeted treatment approach, but also emphasizes the need for surrogate markers to delineate organ damage and monitor the efficacy of enzyme replacement therapy (ERT). Methods: Multiple endothelial factors and plasma homocysteine concentrations were investigated in 12 consecutive hemizygous males with classic Fabry disease and 15 controls as part of an exhaustive baseline evaluation prior to ERT. Results: Compared with the controls, plasma concentrations of homocysteine were significantly (p > 0.01) higher in patients with Fabry disease in the absence of chronic renal failure or vitamin deficiency. Plasma concentrations of vascular cell adhesion molecule‐1 were also significantly (p > 0.05) higher in the patients, and there was a trend for decreased endothelin‐1 levels. No difference was found in serum intercellular adhesion molecule‐1, plasma P‐selectin, serum E‐selectin and plasma thrombomodulin between the patients and controls. Conclusions: The results do not reveal measurable evidence for endothelial and leukocyte activation that could reliably serve as surrogate markers for routine monitoring of the efficacy of ERT in patients with Fabry disease. While the exact origin and clinical significance of hyperhomocysteinaemia in Fabry disease remains to be studied in a larger cohort of patients carefully monitored for their concurrent medications, especially carbamazepine, we suggest that patients may benefit from folic acid or multivitamin therapy to treat this additional vascular risk factor, when present.